药理干预改善阿尔茨海默病患者的睡眠:随机对照试验的元分析
Amy Bedward1, Jasmine Kaur1, Sadiyah Seedat1
1School of Applied Sciences, University of Huddersfield, Huddersfield, West Yorkshire, UK.
Expert review of neurotherapeutics
|April 10, 2024
概括
药理干预在阿尔茨海默病 (AD) 睡眠问题上显示出混合的结果. 虽然 eszopiclone 和 orexin 对抗剂可以改善睡眠,但黑激素的有效性仍然不确定,需要进一步研究.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 老年病的医生 老年病的医生
背景情况:
- 睡眠障碍在阿尔茨海默病 (AD) 中很常见.
- 需要针对AD相关睡眠问题的有效药理干预措施.
研究的目的:
- 系统地审查和元分析随机对照试验 (RCT) 的药理干预措施,以改善AD患者的睡眠.
主要方法:
- 对8个数据库进行系统的文献搜索 (2000年1月至2023年7月).
- 包括将药理干预与安慰剂进行比较的RCT.
- 遵循PRISMA指导方针;在Prospero注册了协议.
主要成果:
- 14个RCT检查了8项干预措施和29个睡眠结果.
- 埃斯索皮克隆和奥雷克辛抗剂改善了睡眠效率.
- 黑激素没有显著的差异;干预措施中断率很低,不良事件很少.
结论:
- 尽管进行了广泛的研究,但对AD睡眠的黑素疗效尚不确定.
- 特拉佐和素受体对抗剂显示出有希望的结果,但需要更多的RCT.
- 进一步的研究是必不可少的,以建立对AD睡眠的最终药理疗法.
相关概念视频
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Management of Insomnia
244
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
244
Sedatives and Hypnotics Drugs: Miscellaneous Agents
171
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
171
Sleepwalking and Sleep Talking
158
Somnambulism, commonly known as sleepwalking, involves individuals engaging in activities ranging from simple walking to more complex behaviors such as driving. Sleepwalking typically occurs during the slow-wave sleep stages 3 and 4 early in the night when the person is not dreaming, contradicting the myth that sleepwalkers are acting out their dreams.
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...
158
Sedatives and Hypnotics: Overview
355
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
355
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468


